Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stéphanie Dulucq

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Genome Medicine|December 3, 2010
The pharmacogenetics of imanitibStéphanie Dulucq, Maja Krajinovic
Cancer Medicine|July 2, 2016
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaStéphanie Dulucq, Francois-Xavier Mahon
Expert Opinion on Drug Metabolism & Toxicology|March 29, 2014
Pharmacogenetic considerations for acute lymphoblastic leukemia therapiesStéphanie Dulucq, Caroline Laverdière, Daniel Sinnett, et al.
British Journal of Haematology|February 20, 2020
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten yearsStéphanie Dulucq, Cyril Astrugue, Gabriel Etienne, et al.
Blood|December 22, 2007
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALLStéphanie Dulucq, Geneviève St-Onge, Vincent Gagné, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2021
Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular ResponseCyril Astrugue, Antoine Bénard, Pauline Bosco-Levy, et al.
Annales De Biologie Clinique|December 21, 2019
[Accreditation strategy for rare somatic molecular abnormalities detected or quantified by polymerase chain reaction: GBMHM recommendations]Pierre Sujobert, Stéphanie Dulucq, Anne Sophie Alary, et al.
Blood|June 6, 2008
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemiaStéphanie Dulucq, Stéphane Bouchet, Béatrice Turcq, et al.
Bulletin Du Cancer|September 4, 2025
[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia]Jean-Michel Cayuela, Stéphanie Dulucq, Sandrine Hayette, et al.
Human Genomics|September 1, 2019
Novel analytical methods to interpret large sequencing data from small sample sizesFlorence Lichou, Sébastien Orazio, Stéphanie Dulucq, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Genome Medicine|December 3, 2010
The pharmacogenetics of imanitibStéphanie Dulucq, Maja Krajinovic
Cancer Medicine|July 2, 2016
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaStéphanie Dulucq, Francois-Xavier Mahon
Expert Opinion on Drug Metabolism & Toxicology|March 29, 2014
Pharmacogenetic considerations for acute lymphoblastic leukemia therapiesStéphanie Dulucq, Caroline Laverdière, Daniel Sinnett, et al.
British Journal of Haematology|February 20, 2020
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten yearsStéphanie Dulucq, Cyril Astrugue, Gabriel Etienne, et al.
Blood|December 22, 2007
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALLStéphanie Dulucq, Geneviève St-Onge, Vincent Gagné, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2021
Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular ResponseCyril Astrugue, Antoine Bénard, Pauline Bosco-Levy, et al.
Annales De Biologie Clinique|December 21, 2019
[Accreditation strategy for rare somatic molecular abnormalities detected or quantified by polymerase chain reaction: GBMHM recommendations]Pierre Sujobert, Stéphanie Dulucq, Anne Sophie Alary, et al.
Blood|June 6, 2008
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemiaStéphanie Dulucq, Stéphane Bouchet, Béatrice Turcq, et al.
Bulletin Du Cancer|September 4, 2025
[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia]Jean-Michel Cayuela, Stéphanie Dulucq, Sandrine Hayette, et al.
Human Genomics|September 1, 2019
Novel analytical methods to interpret large sequencing data from small sample sizesFlorence Lichou, Sébastien Orazio, Stéphanie Dulucq, et al.
Pageof 5